ArticleOral radiology2026
Treatment response assessment in resistant oral squamous cell carcinoma applying
Article in Oral radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThe present study examined the efficacy of the PATIENTS AND
methodsWe included 29 oral squamous cell carcinoma (OSCC) patients with disease progression post the primary treatment, who had
resultsPatients were categorized into a responder group (n = 7) and non-responder group (n = 22). A univariate analysis revealed significant differences in the CT maximum diameter and metabolic tumor volume (p = 0.050, and 0.037, respectively). A multivariate Cox regression analysis revealed a correlation (hazard ratio 3.59, p = 0.046, 95% confidence interval 1.02-12.6) between Lugano-OC and the duration of treatment responses.
conclusionAmong OSCC patients with disease progression post the primary treatment, those with Lugano-OC-localized disease who received radiation chemotherapy had a significantly longer treatment response than patients with advanced-stage disease. These results suggest the predictive value of Lugano-OC for assessing treatment responses in this patient population.
Indexed as
Identifiers
40892203What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.